Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that its first-in-class antibody-blocker therapies for cat and birch allergies have achieved positive outcomes in two Phase 3 clinical trials.
The company confirmed that both trials met their primary and secondary endpoints, demonstrating strong efficacy in reducing allergic responses. The combination therapy was well-tolerated, with no serious adverse events reported throughout the studies.
Encouraged by these results, Regeneron plans to continue developing its allergy pipeline, with additional Phase 3 studies slated to begin in the first half of 2026.
These trials mark a significant step forward in Regeneron’s mission to provide innovative treatments for common allergies, leveraging antibody-blocking technology to offer potential new options for patients affected by cat and birch allergens.
Regeneron Pharmaceuticals stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.